TODDE, SERGIO CAMILLO
 Distribuzione geografica
Continente #
NA - Nord America 5.867
EU - Europa 3.379
AS - Asia 1.289
SA - Sud America 133
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 10.699
Nazione #
US - Stati Uniti d'America 5.750
IT - Italia 658
DE - Germania 631
RU - Federazione Russa 484
SG - Singapore 478
SE - Svezia 466
CN - Cina 439
IE - Irlanda 301
UA - Ucraina 232
GB - Regno Unito 182
HK - Hong Kong 167
FI - Finlandia 129
CA - Canada 109
BR - Brasile 102
AT - Austria 76
FR - Francia 57
ID - Indonesia 50
NL - Olanda 37
DK - Danimarca 36
VN - Vietnam 36
IN - India 26
BE - Belgio 21
JP - Giappone 17
TR - Turchia 17
PL - Polonia 15
CZ - Repubblica Ceca 12
AR - Argentina 10
BG - Bulgaria 10
ZA - Sudafrica 10
IR - Iran 9
KR - Corea 9
MY - Malesia 7
ES - Italia 6
PE - Perù 6
EU - Europa 5
RO - Romania 5
SA - Arabia Saudita 5
BD - Bangladesh 4
CL - Cile 4
EC - Ecuador 4
CO - Colombia 3
DO - Repubblica Dominicana 3
IQ - Iraq 3
MK - Macedonia 3
MX - Messico 3
NZ - Nuova Zelanda 3
PH - Filippine 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
NO - Norvegia 2
PK - Pakistan 2
SN - Senegal 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
ME - Montenegro 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
Totale 10.699
Città #
Ann Arbor 1.568
Fairfield 433
Houston 374
Woodbridge 359
Wilmington 324
Chandler 321
Singapore 298
Ashburn 294
Dublin 284
Jacksonville 245
Dearborn 194
Frankfurt am Main 193
New York 173
Seattle 165
Santa Clara 161
Hong Kong 158
Milan 144
Cambridge 135
Princeton 112
Munich 101
Nanjing 83
Helsinki 67
Vienna 64
Altamura 59
Shanghai 57
Lawrence 49
Jakarta 44
Beijing 43
Lachine 39
Moscow 39
San Diego 34
Council Bluffs 32
Los Angeles 31
Boardman 29
Shenyang 25
Nürnberg 24
Toronto 24
Guangzhou 23
Hebei 23
Rome 23
Brussels 21
Lissone 21
Hefei 20
Tianjin 20
Falls Church 19
Nanchang 19
Andover 18
Changsha 17
Dong Ket 17
Fremont 16
Jiaxing 16
Genoa 15
London 15
Montréal 15
Ottawa 15
Jinan 14
Kunming 11
Ningbo 11
Tokyo 11
Brno 10
Chicago 10
Edmonton 10
Plovdiv 10
Bologna 9
Naples 9
Padova 9
Phoenix 9
São Paulo 9
The Dalles 9
Auburn Hills 8
Huizen 8
Turku 8
Carate Brianza 7
Charlottesville 7
Mountain View 7
Norwalk 7
Turin 7
Washington 7
Bari 6
Catania 6
Detroit 6
Lima 6
Monza 6
Nuremberg 6
Segrate 6
Taizhou 6
University Park 6
Amsterdam 5
Biassono 5
Chengdu 5
Jyväskylä 5
Newark 5
Philadelphia 5
San Mateo 5
Warsaw 5
Zhengzhou 5
Assago 4
Borgo Valsugana 4
Brooklyn 4
Cardano al Campo 4
Totale 7.434
Nome #
Treatment response assessment in [18F]FDG-PET/CT oncology scans: Impact of count statistics variation and reconstruction protocol 408
Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study 394
Study of the Tissue Distribution of TLQP-21 in Mice Using [18F]JMV5763, a Radiolabeled Analog Prepared via [18F]Aluminum Fluoride Chelation Chemistry 377
Cholinergic ligand [C-11]MP4A: Improved 4-acetoxypiperidine precursor synthesis via LC-APCI/MS characterisation and improved radioligand HPLC purification 337
11C-Labelling of N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide Derivatives and Evaluation as Potential Radioligands for PET imaging of Dopamine D3 Receptors 327
Added diagnostic value of respiratory-gated 4D 18F–FDG PET/CT in the detection of liver lesions: a multicenter study 323
In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416 310
A novel versatile precursor suitable for 18F-radiolabeling via “click chemistry” 293
11C-radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]Zofenoprilat 275
Improved synthesis and radiolabeling of [C-11]MP4A, a suitable ligand for the investigation of the cholinergic system using PET 228
18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer 227
VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells 210
Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation 207
Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma 206
Sperimentazione clinica con radiofarmaci 202
EANM Guideline on the validation of analytical methods for radiopharmaceuticals 199
[11C]RN5: A new agent for the in vivo imaging of myocardial α1-adrenoceptors 190
Synthesis and in vivo evaluation of 3-[C-11]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753), as a putative dopamine D-4 receptors antagonist for PET 187
Radiosynthesis of [123I]βCIT, a selective ligand for the study of the dopaminergic and serotoninergic systems in human brain 187
Quality Control in the Production of Radiopharmaceuticals 185
Preparation of [11C]radioligands with high specific radioactivity on a commercial PET tracer synthesizer 182
Development of a bicistronic vector for multimodality imaging of estrogen receptor activity in a breast cancer model: preliminary application 181
Automated production of copper radioisotopes and preparation of high specific activity [(64)Cu]Cu-ATSM for PET studies 176
European regulations for the introduction of novel radiopharmaceuticals in the clinical setting 175
Produzione e verifiche di qualità dei radiofarmaci estemporanei per PET e terapia 174
Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand 173
Systemic and cerebral kinetics of 16α[18F]fluoro-17β-estradiol: A ligand for the in vivo assessment of estrogen receptor binding parameters 173
Sensitive GC-MS method for the determination of specific-activity of 16a[18F]Fluoro-estra-1,3,5(10)-triene-3,17b-diol 171
Rsdiofarmaci marcati con fluoro-18 170
Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals 165
Synthesis and in vivo evaluation of [C-11]CGP62349, a new GABA(B) receptor antagonist 162
PET imaging and single-cell RNA sequencing glioma microenvironment assessment after RT combined therapy 161
Synthesis and carbon-11 labeling of (R)- and (S)-Thionisoxetine, norepinephrine reuptake inhibitors, potential radioligands for Positron Emission Tomography 160
Synthesis and in vivo evaluation of [11C]ICI 118551 as a putative subtype selective β2-adrenergic radioligand 160
Intake risk and dose evaluation methods for workers in radiochemistry labs of a medical cyclotron facility 157
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD) 157
Automation of [C-11]acyl chloride syntheses using commercially available C-11-modules 154
Measurements and evaluation of the risks due to external radiation exposures and to intake of activated elements for operational staff engaged in the maintenance of medical cyclotrons 153
High yield synthesis of [11C]-acetone through selective quenching of methyl lithium 151
Synthesis and automated fluorine-18 radiolabeling of new PSMA-617 derivatives with a CuAAC radiosynthetic approach 148
Measurement and control of the air contamination generated in a medical cyclotron facility for PET radiopharmaceuticals 147
Labeling and evaluation of N-[11C]methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors 143
Synthesis and Biodistribution of (R,S)-[O-Methyl-11C]-1-[3-(5-Methoxy-1,2,3,4-Tetrahydro-1-Naphtalenyl)Propyl]-4-Phenylpiperazine (PNU-157760), A Putative Radioligand for 5-HT1A Receptors 143
PET in psychopharmacology 140
Decommissioning procedures for an 11 MeV self-shielded medical cyclotron after 16 years of working time 139
Clinical Application of a High Sensitivity BGO PET/CT Scanner: Effects of Acquisition Protocols and Reconstruction Parameters on Lesions Quantification 128
Synthesis of [O-methyl-11c]fluvoxamine-a potential serotonin uptake site radioligand 127
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals 127
Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography [2] 125
PET radiopharmacy and automation 124
A PET follow-up study of recovery after stroke in acute aphasics 104
Classificazione ambientale 98
Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals 97
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals 95
Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method 93
From radiotracer to radiopharmaceutical: a philosophical approach 91
Mild synthesis of [N-methyl-11C]-isovaleroyl-(L)-carnitine. The usefulness of a tritium approach. 88
Guidance on current good radiopharmacypractice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective 85
Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models 77
Highlight selection of radiochemistry and radiopharmacy developments by editorial board 69
EANM guideline on quality risk management for radiopharmaceuticals 65
Highlight selection of radiochemistry and radiopharmacy developments by editorial board 61
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals 59
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework 45
Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken' 45
Totale 11.090
Categoria #
all - tutte 39.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 0 0 0 0 24
2020/20211.445 59 71 153 160 117 120 140 112 127 136 106 144
2021/20221.021 89 111 168 136 35 59 62 69 49 59 77 107
2022/20231.344 164 387 84 134 100 197 26 78 71 19 57 27
2023/20241.109 44 40 56 39 147 310 211 40 85 12 8 117
2024/20252.149 137 251 120 98 217 179 202 158 239 341 207 0
Totale 11.090